<DOC>
	<DOCNO>NCT01023815</DOCNO>
	<brief_summary>This study compare follow immunosuppressive regimen recipient kidney transplantation : A ) everolimus , cyclosporine steroid give once-a-day ; B ) everolimus cyclosporine give twice day steroid withdrawal ; C ) everolimus , cyclosporine give twice day continuous steroid . The purpose study evaluate regimens A B comparison control group ( group C ) efficacy , use main endpoint treatment failure rate , composite endpoint include death , graft loss , BPAR lose follow-up randomization Month 12 .</brief_summary>
	<brief_title>Once-a-day Regimen With Everolimus , Low Dose Cyclosporine Steroids Comparison With Steroid Withdrawal Twice Day Regimen With Everolimus , Low Dose Cyclosporine Steroids .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Inclusion criterion : recipient 1st 2nd single kidney transplant donor age &gt; 14 year females capable become pregnant must negative serum pregnancy test within 7 day prior Baseline ( Visit 2 ) , required practice approve method birth control duration study period 2 month follow discontinuation study medication patientswho willing able participate study write informed consent obtain Exclusion criterion : Exclusion criterion screen ( pretransplantation , Visit 1 ) : recipient kidneypancreas transplant , double kidney transplant recipients 2nd kidney transplant lose 1st immunological reason focal segmental glomerulosclerosis ( FSGS ) , primary oxaluria disease ( cause end stage renal failure ESRF ) high risk rapid recurrence require continuous corticosteroid treatment recipient ABO incompatible transplant historical current peak PRA &gt; 25 % ( current = 3 month ) patient already exist antibody donor thrombocytopenia ( platelet &lt; 75,000/mm³ ) , absolute neutrophil count &lt; 1,500/mm³ , leucopenia ( leucocytes &lt; 2,500/mm³ ) , hemoglobin &lt; 6 g/dL symptom significant somatic mental illness . Inability cooperate communicate investigator , comply study requirement , give informed consent history malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis patient HIV positive Hepatitis B surface antigen positive ( HbsAg ) ; HCV positive patient receive interferon and/or ribavirin evidence severe liver disease ( incl . abnormal liver enzyme profile , i.e . AST , ALT total bilirubin &gt; 3 time UNL ) evidence drug alcohol abuse body mass index ( BMI ) &gt; 35 patient need treat drug know strongly interact CsA and/or everolimus ( detailed Appendix 2 protocol ) exclude , accord investigator interfere objective study woman childbearing potential , UNLESS use two birth control method . The two method double barrier method barrier method plus hormonal method pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever long history hypersensitivity study drug drug similar chemical class patient severe active infection medical condition ( ) view investigator prohibit participation study ( specify require ) Additional exclusion criterion posttransplantation ( Visit 2 ) : • graft perfuse thrombosis main vessel , accord angioscintigraphy echocolordoppler within 48 hour end surgical procedure To avoid possible influence confound factor result study additional exclusion criterion randomization ( Visit 5 , Month 3 ) : unsatisfactory renal function ( CrCl accord Cockcroft Gault &lt; 40 mL/min ) proteinuria ≥0.8 g/24 hr steroidresistant , humoral , moderate/severe ( BANFF grade ≥II ) biopsy proven acute rejection multiple ( 2 ) biopsy proven treat acute rejection acute rejection lead relevant loss renal function acute rejection impairment renal function ( increase serum creatinine &gt; 30 % ) month precede randomization severe/uncontrollable adverse event suspect relationship everolimus ( e.g . anemia , oral aphtosis , arthralgia ) control investigator plan withdrawal everolimus severe infection require hospitalization two week precede randomization poor compliance prescribe treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>once-a-day regimen</keyword>
	<keyword>steroid withdrawal</keyword>
	<keyword>drug minimization</keyword>
	<keyword>immunosuppression prevention acute rejection</keyword>
</DOC>